Question 63: Did transformation to acute myelogenous leukemia (AML) occur?
Indicate if the recipient’s disease transformed to AML between initial diagnosis and the start of the preparative regimen. Approximately 10-15% of JMML cases will transform to AML. Progression to AML is generally defined by an increase in blood or bone marrow blasts (≥ 20%). If the patient’s disease transformed to AML, also complete AML Pre-HCT Data, Form 2010.
Question 64: Date of transformation
Enter the date of the assessment that determined the disease transformation. Report the date of the first pathological diagnosis (i.e., bone marrow biopsy) of AML. Enter the date the sample was collected for examination. If the diagnosis was determined at an outside center and no documentation of a pathological or laboratory assessment is available, the dictated date of diagnosis within a physician note may be reported. Do not report the date symptoms first appeared.
If the exact date is not known, use the process described for reporting partial or unknown dates in General Instructions, Guidelines for Completing Forms.
Need more help with this?
Don’t hesitate to contact us here.